Cancer Drug Resistance
In August, Cancer Drug Resistance is accepted for inclusion in Emerging Sources Citation Index (ESCI).
In May, Cancer Drug Resistance (CDR) is officially indexed in PubMed Central® (PMC).
In March, Cancer Drug Resistance (CDR) was indexed in Scopus.
In December, the estimated impact factor was 2.461. The total citations of papers published in 2018 and 2019 were 224 times, and the total number of reviews and original articles published were 91. Click the link for details of the CDR citation: https://oaepublishstorage.blob.core.windows.net/cdruploadedfiles/Citations_of_CDR_as_of_Dec_31_2020.xls.
In August, the work of expanding the Editorial Board of CDR came to a successful conclusion. A total of 30 scientists with significant international influence in the field of cancer drug resistance joined the Editor Board, with the ambition to help create a better future for CDR.
In March, CDR became a member of the Committee on Publication Ethics (COPE).
In March, CDR was founded with Professor Godefridus J. Peters as the Editor-in-Chief. The inaugural issue was officially released online on March 19, 2018.
